Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Ondansetron Hydrochloride
Brand Name
Ondansetron Hydrochloride
Generic Name
Ondansetron Hydrochloride
Active Ingredient
OndansetronCategory
Serotonin-3 Receptor Antagonist [EPC]
Variants
73
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 4 mg/1 | TABLET, FILM COATED | ORAL | 62756-130 |
| 8 mg/1 | TABLET, FILM COATED | ORAL | 68788-8582 |
| 8 mg/1 | TABLET, FILM COATED | ORAL | 85509-1076 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ondansetron Hydrochloride, you must consult a qualified healthcare professional.
| 4 mg/1 | TABLET, FILM COATED | ORAL | 60760-636 |
| 8 mg/1 | TABLET, FILM COATED | ORAL | 68071-1742 |
| 8 mg/1 | TABLET, FILM COATED | ORAL | 68084-221 |
| 4 mg/1 | TABLET, FILM COATED | ORAL | 68788-9368 |
| 4 mg/1 | TABLET, FILM COATED | ORAL | 70518-1585 |
| 4 mg/1 | TABLET, FILM COATED | ORAL | 72789-034 |
| 8 mg/1 | TABLET, FILM COATED | ORAL | 76420-916 |
| 2 mg/mL | INJECTION | INTRAMUSCULAR, INTRAVENOUS | 83270-160 |
| 2 mg/mL | INJECTION | INTRAMUSCULAR, INTRAVENOUS | 83270-161 |
+ 38 more variants
Detailed information about Ondansetron Hydrochloride
Ondansetron is a potent serotonin-3 (5-HT3) receptor antagonist used to prevent nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery. It works by blocking serotonin signals in the gut and brain that trigger the emetic reflex.
The dosage of ondansetron varies significantly based on the indication and the patient's specific medical history. Healthcare providers typically follow these general guidelines:
For pediatric patients, dosing is often calculated based on body weight or body surface area (BSA).
No dosage adjustment is generally required for patients with renal (kidney) impairment. The pharmacokinetic parameters remain relatively stable in this population.
For patients with severe hepatic (liver) impairment (Child-Pugh score of 10 or greater), the total daily dose should not exceed 8 mg. This is because the liver is the primary site of metabolism, and severe dysfunction can lead to significantly higher drug levels in the blood.
While no specific dose adjustments are mandated by age alone, healthcare providers usually exercise caution in the elderly due to the higher prevalence of underlying heart conditions or electrolyte imbalances that could increase the risk of side effects.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up. Since this medication is often taken on an 'as needed' basis for certain conditions, you may not be on a strict schedule.
Symptoms of an ondansetron overdose may include sudden vision loss, severe constipation, feeling light-headed, or fainting. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for ondansetron; treatment is supportive and symptomatic.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a return of severe nausea and vomiting.
Most patients tolerate ondansetron well, but some side effects are frequently reported. These are generally mild and self-limiting:
Ondansetron is a potent medication that must be used with caution in patients with specific underlying health conditions. It is not a general treatment for simple 'upset stomach' and should only be used for the indications prescribed by a physician.
No FDA black box warnings for Ondansetron. However, clinicians must strictly adhere to the maximum dose limits, especially in patients with liver disease or those at risk for heart rhythm disturbances.
Ondansetron is frequently used off-label for severe nausea and vomiting of pregnancy (hyperemesis gravidarum). However, its use during pregnancy remains a subject of clinical debate.
It is not known whether ondansetron is excreted in human breast milk, although animal studies have shown excretion in the milk of lactating rats. Because many drugs are excreted in human milk, caution should be exercised. The decision to breastfeed while taking ondansetron should consider the clinical need of the mother and any potential adverse effects on the nursing infant.
Ondansetron is a competitive, highly selective antagonist of the 5-hydroxytryptamine type 3 (5-HT3) receptor. It does not have any significant affinity for other serotonin receptors (5-HT1, 5-HT2, 5-HT4), dopamine receptors, or alpha-adrenergic receptors. By binding to 5-HT3 receptors on the vagus nerve and in the area postrema (the vomiting center of the brain), it prevents the initiation of the emetic reflex. This dual central and peripheral action makes it exceptionally effective for chemo-induced symptoms.
Common questions about Ondansetron Hydrochloride
Ondansetron is primarily used to prevent and treat nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It belongs to a class of drugs called 5-HT3 receptor antagonists, which work by blocking serotonin in the body that triggers the vomiting reflex. While it is highly effective for these specific medical triggers, it is not typically used for motion sickness or general stomach upset. Your doctor may also prescribe it off-label for severe pregnancy-related nausea if other treatments have failed. It is available in several forms, including tablets, dissolving strips, and injections.
The most frequently reported side effect of ondansetron is a headache, which occurs in about 10-25% of patients. Constipation is also very common because the drug slows down the movement of the digestive tract. Some people may experience a general feeling of tiredness, drowsiness, or dizziness shortly after taking a dose. Less common effects include a feeling of warmth or flushing in the face and chest. Most of these side effects are mild and go away once the medication is stopped. If you experience a severe headache or significant constipation, you should consult your healthcare provider.
There is no specific chemical interaction between alcohol and ondansetron that is considered dangerous. However, healthcare providers generally advise against drinking alcohol while you are experiencing nausea or vomiting, as alcohol can irritate the stomach and worsen your symptoms. Alcohol can also increase the risk of side effects like dizziness and dehydration. Since ondansetron is often used during chemotherapy or after surgery, your body is already under significant stress, and alcohol may interfere with your recovery. Always check with your doctor before consuming alcohol while on any medication.
Ondansetron is sometimes used for severe morning sickness, but its safety during pregnancy is a complex topic. Some studies have suggested a very small increased risk of heart defects or oral clefts when taken during the first trimester, while other large studies have found no such risks. Because of this conflicting data, the FDA suggests using other treatments first before turning to ondansetron. It is generally reserved for women with hyperemesis gravidarum who cannot keep food or fluids down. You must have a thorough discussion with your obstetrician to weigh the benefits against the potential risks to the developing fetus.
The onset of action for ondansetron depends on the form you are taking. When taken as an oral tablet or an orally disintegrating tablet (ODT), it typically begins to work within 30 to 60 minutes, reaching its peak effect in about 2 hours. If it is administered intravenously (IV) by a healthcare professional, the effect is almost immediate, often working within minutes. For chemotherapy, it is usually taken 30 minutes before the treatment starts to ensure it is active in your system when the nausea-inducing chemicals are released. Its effects generally last for about 8 to 12 hours.
Yes, you can typically stop taking ondansetron suddenly without experiencing withdrawal symptoms. It is not an addictive medication and does not require a tapering period. However, if you are still undergoing chemotherapy or radiation, stopping the medication early may cause your nausea and vomiting to return quickly. It is best to follow the full schedule prescribed by your doctor, even if you feel fine. If you are taking it 'as needed' for postoperative recovery, you can stop whenever your symptoms have completely resolved.
If you miss a dose of ondansetron, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule; never take two doses at once to make up for a missed one. Since this medication is often timed specifically around chemotherapy or radiation sessions, missing a dose could lead to breakthrough nausea. If you miss a dose specifically before a treatment session, contact your oncology clinic for instructions. Keeping a consistent schedule is the best way to prevent nausea before it starts.
Weight gain is not a recognized side effect of ondansetron. In fact, because the medication is used to treat nausea and vomiting, it often helps patients maintain their weight by allowing them to eat and drink during difficult treatments like chemotherapy. If you notice rapid weight gain or swelling (edema) while taking this medication, it is more likely related to your underlying condition or other medications, such as steroids. Some patients may experience bloating due to constipation, which can feel like weight gain. Always report sudden changes in weight to your healthcare team.
Ondansetron can interact with several other medications, some of which are very serious. It should never be taken with apomorphine, as this can cause a dangerous drop in blood pressure. You should also be cautious if you take antidepressants (like SSRIs or SNRIs), as the combination can lead to a rare but life-threatening condition called Serotonin Syndrome. Additionally, drugs that affect your heart rhythm can increase the risk of heart complications when combined with ondansetron. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are currently taking.
Yes, ondansetron is widely available as a generic medication and is significantly less expensive than the original brand-name version, Zofran. Generic versions are available in all standard forms, including regular tablets, orally disintegrating tablets (ODT), and oral solutions. The FDA requires generic drugs to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. This means the generic version will work in the exact same way as Zofran. Most insurance plans cover the generic version of ondansetron as a preferred medication.
Other drugs with the same active ingredient (Ondansetron)
> Warning: Stop taking Ondansetron and call your doctor immediately if you experience any of these serious symptoms:
Ondansetron is typically used for short-term symptom management (1 to 5 days). There is limited clinical data on the effects of daily, long-term use over months or years. Prolonged use may lead to chronic constipation or a potential masking of underlying gastrointestinal conditions. If long-term use is being considered, healthcare providers will typically monitor liver function and cardiac health more closely.
As of 2026, there are no FDA black box warnings for ondansetron. However, the FDA has issued multiple safety communications regarding the risk of QT prolongation, particularly with high intravenous doses. Specifically, the 32 mg single IV dose was removed from the market several years ago due to this cardiac risk.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Healthcare providers may require the following monitoring for certain patients:
Ondansetron may cause dizziness or drowsiness in some individuals. Patients should observe how they react to the medication before driving, operating heavy machinery, or performing tasks that require mental alertness.
There is no known direct chemical interaction between alcohol and ondansetron. However, alcohol can worsen nausea and increase the likelihood of dizziness or dehydration. It is generally recommended to avoid alcohol while being treated for nausea and vomiting.
Ondansetron does not typically require a tapering schedule when used for short-term antiemetic therapy. There is no recognized withdrawal syndrome. However, stopping the medication while still undergoing chemotherapy or radiation may result in a rapid return of severe symptoms.
> Important: Discuss all your medical conditions, especially heart or liver problems, with your healthcare provider before starting Ondansetron.
Ondansetron is not known to interfere with common laboratory tests, though it may cause transient elevations in liver function tests (ALT/AST) as a side effect, which could be misinterpreted as liver disease.
Management Strategy: If you are taking a medication that interacts with ondansetron, your doctor may adjust your dose, monitor your heart rhythm via ECG, or choose an alternative antiemetic.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.
There is a potential for cross-sensitivity between ondansetron and other 5-HT3 receptor antagonists, such as granisetron (Kytril), dolasetron (Anzemet), or palonosetron (Aloxi). If a patient has had a severe allergic reaction to one drug in this class, they should generally avoid all others unless specifically directed by an allergist or specialist.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart rhythm problems or allergies, before prescribing Ondansetron.
Ondansetron is FDA-approved for the prevention of CINV in children as young as 4 years old and for PONV in infants as young as 1 month old.
Clinical trials have included a significant number of patients over 65. No overall differences in safety or effectiveness were observed between these patients and younger patients. However, older adults are more likely to have decreased hepatic function and are more susceptible to QT prolongation. ECG monitoring is more frequently recommended for this age group.
Patients with kidney disease do not require a dose reduction. The drug is primarily cleared by the liver. Even patients on hemodialysis do not appear to require a change in their dosing schedule.
In patients with severe hepatic impairment (Child-Pugh Class C), the clearance of ondansetron is reduced by up to 50%, and the half-life can increase to 20 hours. For these patients, a maximum daily dose of 8 mg is recommended to prevent drug accumulation and toxicity.
> Important: Special populations require individualized medical assessment to ensure the safest possible treatment outcome.
| Parameter | Value |
|---|---|
| Bioavailability | ~60% (Oral) |
| Protein Binding | 70% - 76% |
| Half-life | 3 - 6 hours (Adults) |
| Tmax | 1.5 - 2 hours (Oral) |
| Metabolism | Hepatic (CYP3A4, 2D6, 1A2) |
| Excretion | Renal (95% as metabolites), Fecal (<5%) |
Ondansetron is the prototype of the 'setron' class of drugs. Other members include Granisetron, Dolasetron, and Palonosetron. It is classified as a Serotonin-3 Receptor Antagonist [EPC].